Welcome to our dedicated page for Envista Holdings SEC filings (Ticker: NVST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Envista Holdings Corporation (NYSE: NVST) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed information about its dental products business. As a Delaware-incorporated public company with common stock registered under Commission File Number 001-39054, Envista uses SEC filings to report on financial results, governance changes, and other material events related to its global family of dental brands.
On this page, investors can review Envista’s core periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s segments, such as Specialty Products & Technologies and Equipment & Consumables, along with risk factors, management discussion, and financial statements. Current reports on Form 8-K disclose specific developments, such as quarterly earnings releases, the publication of a Sustainability Report covering environmental, social, and governance topics, and changes in the composition of the Board of Directors.
Envista’s 8-K filings include items reporting results of operations and financial condition, where the company furnishes press releases detailing sales, net income, adjusted EBITDA, and business highlights for recent quarters. Other 8-K items address Regulation FD disclosures, such as slide decks used on earnings calls or references to sustainability and investor presentations, as well as board-level changes like the resignation of a director.
Through Stock Titan, these SEC filings are updated from EDGAR and can be paired with AI-powered summaries that explain key points in accessible language. Users can quickly identify the most relevant sections of Envista’s 10-K and 10-Q reports, understand the implications of 8-K announcements, and access information related to the company’s capital structure and governance. This page also serves as a starting point for tracking any future Forms 4 or proxy materials that may detail insider transactions or executive compensation, as they become available in Envista’s regulatory record.
The Vanguard Group filed an amended Schedule 13G reporting that, following an internal realignment, it holds 0 shares of Envista Holdings Corp common stock, representing 0% of the class. The filing explains certain subsidiaries now report disaggregated beneficial ownership in reliance on SEC Release No. 34-39538, and that The Vanguard Group, Inc. no longer is deemed to have beneficial ownership over securities held by those subsidiaries. The amendment lists the issuer address as 200 South Kraemer Blvd, Brea, CA and the filer address as 100 Vanguard Blvd., Malvern, PA. The report is signed by Ashley Grim as Head of Global Fund Administration on 03/26/2026.
Envista Holdings Corp Chief Financial Officer Eric D. Hammes reported multiple equity transactions. He received 29,225 Performance Share Units and 38,040 stock options that vest over three years, along with 16,055 restricted stock units that also vest annually over three years.
In a related tax-withholding transaction, 2,045 shares of common stock were withheld at $29.59 per share to cover taxes on vesting RSUs, rather than sold in the open market. After these transactions, his directly held common stock increased to 110,798 shares, with additional unvested equity awards outstanding.
Envista Holdings Corp reported insider equity awards for Veronica Acurio, President, Orthodontics. On the reported date, she received grants of 13,845 Performance Share Units and 18,020 stock options, along with a 7,605-share award of common stock in the form of restricted stock units.
The performance units may ultimately pay out between 0%-200% of the 13,845 target amount based on achievement of specified performance measures over a three-year period. The option grant and restricted stock units vest in equal installments on each anniversary of grant over three years, conditioned on continued service.
The filing also shows a disposition of 1,412 common shares at $29.59 per share to satisfy tax withholding obligations tied to vesting RSUs, a non-open-market transaction. After these transactions, Acurio directly held 56,516 shares of Envista common stock.
Envista Holdings Corp reported insider equity awards for executive Stefan Nilsson, President, Nobel Biocare. He received 13,845 Performance Share Units that may pay out from 0% to 200% of target based on three-year performance, and an option for 18,020 shares vesting over three years.
Nilsson was also granted 7,605 Restricted Stock Units, which vest ratably over three years and convert into common shares on a 1-for-1 basis. In a related move, 182 common shares were withheld and disposed of to cover tax obligations upon RSU vesting.
Envista Holdings Corp executive Mischa Reis reported mixed equity compensation activity. On February 25, Reis received 10,770 Performance Share Units that may vest over a three-year performance period, with actual payout ranging from 0% to 200% of this target amount based on performance certification.
On the same date, Reis was granted 14,020 stock options that vest in three equal annual installments, and 5,915 restricted stock units that also vest ratably over three years, each converting into one share of common stock. In connection with the vesting of previously granted RSUs, 2,976 shares of common stock were withheld at $29.59 per share to cover tax obligations, reducing open-market impact. After these transactions, Reis directly owned 35,321 shares of common stock.
Envista Holdings Corp General Counsel Mark E. Nance reported equity compensation changes and related tax withholding. On February 25, 2026, he received 23,070 Performance Share Units, which can pay out between 0%-200% of this target amount based on three-year performance measures.
He was also granted 30,040 stock options that vest in equal annual installments over three years, and 12,675 shares of common stock tied to Restricted Stock Units that vest ratably on each anniversary of the grant date over three years. To cover tax obligations from RSU vesting, 3,368 shares of common stock were withheld at $29.59 per share, reducing the need for a separate cash payment.
Envista Holdings Corp Chief Accounting Officer Faez C. Kaabi reported two equity-related transactions involving company common stock. On the same date, 4,964 shares were disposed of at $29.59 per share to satisfy tax withholding obligations tied to the vesting of previously granted stock-settled RSUs.
Kaabi also acquired 13,520 RSUs as a grant that will vest in three equal annual installments, each RSU converting into one share of common stock upon vesting, subject to continued service. Following these transactions, Kaabi directly owned 58,552 shares of Envista common stock.
Envista Holdings Corp CEO Paul A. Keel reported a mix of equity awards and a small tax‑related share disposition. He received 132,885 Performance Share Units, which can pay out between 0% and 200% of this target amount based on three‑year performance goals. He was also granted 115,320 stock options and 48,670 Restricted Stock Units, each scheduled to vest in equal installments over three years, contingent on continued service. To cover tax withholding on vested RSUs, 11,840 common shares were withheld at $29.59 per share, leaving him with 384,385 common shares directly owned.
Envista Holdings Corp reported that Robert Befidi, its President, Diagnostics, received several equity awards. He was granted 13,845 Performance Share Units, which can pay out between 0% and 200% of this target amount depending on performance over a three-year period.
He also received 18,020 employee stock options that vest in three equal annual installments, and 7,605 restricted stock units that likewise vest ratably over three years, all subject to continued service. Separately, 2,177 common shares were withheld at $29.59 per share to cover tax obligations on vesting RSUs, leaving him with 50,932 common shares directly owned.
Envista Holdings Corporation reports 2025 sales of $2.7 billion, up from $2.5 billion in 2024, driven by its global dental product portfolio. The Specialty Products & Technologies segment contributed 64% of sales, with Equipment & Consumables providing 36%.
North America generated 51% of revenue, Western Europe 23%, emerging markets 22%, and other developed markets 4%. Emerging market sales reached $586 million. The company highlights growth in implants, orthodontic clear aligners and digital imaging, alongside a strong focus on EBS-driven cost control, R&D investment and human capital development.